Recombinant Human MAdCAM-1 Fc Chimera Protein, CF
Recombinant Human MAdCAM-1 Fc Chimera Protein, CF Summary
Why choose R&D Systems MAdCAM-1 Protein?
- Guaranteed Bioactivity and High Purity: Bioactivity tested by functional ELISA and purity determined by SDS-PAGE to be greater than 90%.
- Lot-to-Lot Consistency: Stringent QC testing performed on each lot to ensure consistent activity and purity.
- Bulk Quantities Available: Bulk up and save with large mass quantities to meet your research needs. Supply agreements available, partner with us. Please contact us.
- Most Respected, Most Cited Brand in Proteins: With over 35 years of providing the best recombinant proteins to the scientific community, R&D Systems continues to lead the industry in quality, activity, and purity.
Product Specifications
Optimal dilutions should be determined by each laboratory for each application.
| Human MAdCAM-1 Met1-Gln333 Accession # AAY82472 |
IEGRMD | Human IgG1 (Pro100-Lys330) |
| N-terminus | C-terminus | |
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
6056-MC
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
| Reconstitution | Reconstitute at 200 μg/mL in PBS. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Reconstitution Calculator
Background: MAdCAM-1
Mucosal addressin cell adhesion molecule-1 (MAdCAM-1) is an approximately 60 kDa type 1 transmembrane glycoprotein. It is an endothelial cell adhesion molecule that belongs to the immunoglobulin (Ig) superfamily of proteins (1). Human MAdCAM-1 is synthesized as a 382 amino acid (aa) precursor that contains an 18 aa signal sequence, a 299 aa extracellular domain (ECD), a 21 aa transmembrane segment, and a 44 aa cytoplasmic tail. Within the ECD there is one potential site for N-linked glycosylation (2). The ECD comprises two Ig-like domains of 90 aa and 119 aa, respectively, each possessing invariant cysteine residues that stabilize the Ig loop (2). There is also a Ser-Thr-Pro-rich (71%) mucin-like 48 aa domain that is (aa 206 ‑ 317) formed by six tandem repeats of an eight aa sequence having the general consensus DTTSPEP/SP. This mucin domain contains 19 potential sites for O-linked glycosylation (2, 3). A splicing variant in which a single Ala residue is substituted for aa 223 ‑ 334 in isoform 1 produces a second isoform. Human mature MAdCAM-1 shares only 44% aa sequence identity with mature mouse MAdCAM-1. The integrin alpha (4) beta (7), which is expressed on lymphocytes, functions as the MAdCAM-1 receptor (1). The Ig domains of MAdCAM-1 are critical to alpha (4) beta (7) binding, and the mucin domain has activity in L‑Selectin binding. MAdCAM-1 expression is up-regulated by TNF-alpha and IL‑1 beta. MAdCAM-1 is expressed on the surface of high endothelial venules (HEV) in the gut and in Peyer’s patches, on endothelial cells of the mesenteric lymph nodes, lamina propria of the small and large intestine, and the mammary gland during lactation, and on brain endothelial cells (1). MAdCAM‑1 has also been reported to be expressed in the liver portal region in autoimmune hepatitis (1), and in bone marrow following allogenic (genetically non-identical) hematopoietic stem cell transplantation, where it recruits donor T cells, which may lead to graft versus host disease (3, 4). MAdCAM‑1 functions as a homing receptor, and plays a central role in leukocyte migration into HEVs and Peyer’s patch (5). In addition to its normal role in lymphocyte trafficking to mucosal tissue, MAdCAM‑1 expression is also dramatically increased in chronic inflammatory and disease states (1, 6), including inflammatory bowel disease (Crohn’s disease and ulcerative colitis) (7), sclerosing cholangitis (8), and diabetes (9), and may play an important role in these conditions.
- Ando, T. et al. (2007) BMC Physiol. 7:10.
- Dando, J. et al. (2002) Acta Crystallogr. D 58:233.
- Leung, E. et al. (1996) Immunol. Cell Biol. 74:490.
- Ambruzova, Z. et al. (2009) Hum. Immunol. 70:457.
- Tada, T. et al. (2008) Exp. Anim. 57:247.
- Volpes, R. et al. (1992) Hepatology 15:269.
- Connor, E.M. et al. (1999) J. Leukoc. Biol. 65:349.
- Ala, A. et al. (2001) Gut 49:3043.
- Yang, X.D. et al. (1997) Diabetes 46:1542.
Citations for Recombinant Human MAdCAM-1 Fc Chimera Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
15
Citations: Showing 1 - 10
Filter your results:
Filter by:
-
The Force-Dependent Mechanism of an Integrin ?4?7-MAdCAM-1 Interaction
Authors: Su, Y;Luo, Z;Sun, D;Yang, B;Li, Q;
International journal of molecular sciences
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
E-selectin-mediated rapid NLRP3 inflammasome activation regulates S100A8/S100A9 release from neutrophils via transient gasdermin D pore formation
Authors: Pruenster, M;Immler, R;Roth, J;Kuchler, T;Bromberger, T;Napoli, M;Nussbaumer, K;Rohwedder, I;Wackerbarth, LM;Piantoni, C;Hennis, K;Fink, D;Kallabis, S;Schroll, T;Masgrau-Alsina, S;Budke, A;Liu, W;Vestweber, D;Wahl-Schott, C;Roth, J;Meissner, F;Moser, M;Vogl, T;Hornung, V;Broz, P;Sperandio, M;
Nature immunology
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Force-Regulated Calcium Signaling of Lymphoid Cell RPMI 8226 Mediated by Integrin ?4?7/MAdCAM-1 in Flow
Authors: Sun, D;Luo, Z;Kong, Y;Huang, R;Li, Q;
Biomolecules
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Irisin supports integrin-mediated cell adhesion of lymphocytes
Authors: PK Myint, A Ito, MG Appiah, G Obeng, S Darkwah, E Kawamoto, A Gaowa, EJ Park, M Shimaoka
Biochemistry and Biophysics Reports, 2021-03-08;26(0):100977.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay, ELISA Capture Control -
Circulating exosomes express &alpha4&beta7 integrin and compete with CD4+ T cells for the binding to Vedolizumab
Authors: R Domenis, M Marino, A Cifù, G Scardino, F Curcio, M Fabris
PLoS ONE, 2020-11-12;15(11):e0242342.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Baseline levels of dynamic CD4+ T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort study
Authors: C Allner, M Melde, E Becker, F Fuchs, L Mühl, E Klenske, L Müller, N Morgenster, K Fietkau, S Hirschmann, R Atreya, I Atreya, MF Neurath, S Zundler
BMC Gastroenterol, 2020-04-15;20(1):103.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Sialyltransferase inhibition leads to inhibition of tumor cell interactions with E-selectin, VCAM1, and MADCAM1, and improves survival in a human multiple myeloma mouse model
Authors: A Natoni, ML Farrell, S Harris, C Falank, L Kirkham-Mc, MS Macauley, MR Reagan, M O' Dwyer
Haematologica, 2020-01-31;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease
Authors: C Lichnog, S Klabunde, E Becker, F Fuh, P Tripal, R Atreya, E Klenske, R Erickson, H Chiu, C Reed, S Chung, C Neufert, I Atreya, J McBride, MF Neurath, S Zundler
Front Pharmacol, 2019-02-01;10(0):39.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to ?4?7
Authors: S Lertjuthap, C Cicala, D Van Ryk, M Liu, J Yolitz, D Wei, F Nawaz, A Doyle, B Horowitch, C Park, S Lu, Y Lou, S Wang, R Pan, X Jiang, F Villinger, SN Byrareddy, PJ Santangelo, L Morris, CK Wibmer, K Biris, RD Mason, J Gorman, J Hiatt, E Martinelli, M Roederer, D Fujikawa, G Gorini, G Franchini, A Arakelyan, AA Ansari, K Pattanapan, XP Kong, AS Fauci, J Arthos
PLoS Pathog., 2018-08-28;14(8):e1007278.
Species: Human
Sample Types: Recombinant Protein
Applications: Bioassay, Surface Plasmon Resonance -
??CD4effector/effector memory T cells differentiate into productively and latently infected central memory T cells by TGF?1 during HIV-1 infection
Authors: KW Cheung, T Wu, SF Ho, YC Wong, L Liu, H Wang, Z Chen
J. Virol., 2018-03-28;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
RAR?/RXR Synergism Potentiates Retinoid Responsiveness in Cutaneous T Cell Lymphoma Cell Lines
Authors: L Wang, SS DeMarco, MS Peaks, AL Maiorana-B, J Chen, MJ Crouch, BM Shewchuk, SR Shaikh, CM Phillips, LC Bridges
Exp. Dermatol., 2017-07-03;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to alpha4beta7 Integrin Receptor.
Authors: Peachman K, Karasavvas N, Chenine A, McLinden R, Rerks-Ngarm S, Jaranit K, Nitayaphan S, Pitisuttithum P, Tovanabutra S, Zolla-Pazner S, Michael N, Kim J, Alving C, Rao M
PLoS ONE, 2015-12-01;10(12):e0143895.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Envelope glycoprotein binding to the integrin alpha4beta7 is not a general property of most HIV-1 strains.
Authors: Perez L, Chen H, Liao H, Montefiori D
J Virol, 2014-07-09;88(18):10767-77.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
The alpha4beta7 integrin binds HIV envelope but does not mediate bystander killing of gamma/delta T cells.
Authors: Li H, Pauza CD
Blood, 2012-07-19;120(3):698-9.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
HIV envelope-mediated, CCR5/alpha4beta7-dependent killing of CD4-negative gammadelta T cells which are lost during progression to AIDS.
Authors: Li H, Pauza CD
Blood, 2011-09-16;118(22):5824-31.
Species: Human
Sample Types: Whole Cells
Applications: Binding Assay
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Human MAdCAM-1 Fc Chimera Protein, CF
Average Rating: 5 (Based on 3 Reviews)
Have you used Recombinant Human MAdCAM-1 Fc Chimera Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
Reason for Rating: this protein worked out well in my adhesion assay. Following the instruction provided, I successfully validated the inhibitory function of my compounds.
